INTERNATIONAL DESK: Covaxin maker Bharat Biotech is targeting to make one billion doses annually of its intranasal vaccine in 2022 that is under clinical trials now.
The Hyderabad-based vaccine maker is also looking for global partners to manufacture and distribute the vaccine overseas. BBV154, the intranasal vaccine, can be administered as a nasal spray or a drop.
It cannot be taken at home though, but needs to be administered in a clinical setting. The adenovirus vector-based vaccine helps trigger generation of IgA antibodies that line the nasal mucosa. (Business Standard)
iNews covers the latest and most impactful stories across
entertainment,
business,
sports,
politics, and
technology,
from AI breakthroughs to major global developments. Stay updated with the trends shaping our world. For news tips, editorial feedback, or professional inquiries, please email us at
[email protected].
Get the latest news first by following us on
Google News,
Twitter,
Facebook,
Telegram
, and subscribe to our
YouTube channel.
